Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035235 | 0.93 | PPARG (0.44) | PPARGTAAR1ALKBH1SCN9ATSHR | |
| SCHEMBL1633669 | 0.91 | PPARG (0.43) | PPARGTAAR1SCN9ATSHRSMN1; SMN2 | |
| SCHEMBL6035621 | 0.90 | PPARG (0.44) | PPARGTAAR1PPARDPPARA | |
| SCHEMBL6035784 | 0.89 | PPARG (0.41) | PPARGTAAR1TSHRSMN1; SMN2PPARD | |
| SCHEMBL6034930 | 0.88 | PPARG (0.47) | PPARGSMN1; SMN2ALDH1A1 | |
| SCHEMBL6036096 | 0.88 | PPARG (0.47) | PPARGALKBH1SCN9AALDH1A1 | |
| SCHEMBL6035894 | 0.87 | PPARG (0.44) | PPARGTAAR1SCN9ATSHRSMN1; SMN2 | |
| SCHEMBL6036112 | 0.87 | PPARG (0.40) | PPARGTAAR1TSHRSMN1; SMN2PPARD | |
| SCHEMBL6034618 | 0.87 | PPARG (0.46) | PPARGALKBH1SCN9APPARDALDH1A1 | |
| SCHEMBL6035887 | 0.85 | PPARG (0.43) | PPARGTAAR1SCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARG 1037/4885TAAR1 2368/4885ALKBH1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.